drugset / Trial / NCT03613181
ANG1005 in Leptomeningeal Disease From Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label Phase 3 study to see if ANG1005 can prolong survival compared to a Physician Best Choice control in HER2-negative breast cancer patients with newly diagnosed leptomeningeal disease and previously treated brain metastases.
Timeline
- Start
- 2023-12
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANG1005 | Peptide | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Eribulin | Small molecule | — | — |
| Subject | Methotrexate | Small molecule | — | Intravenous |